Optimal duration of anticoagulant therapy after an episode of venous thromboembolism

Blood Coagulation and Fibrinolysis

Volumn 11, Issue 8, 2000, Pages 701-707

  Pinede, L ^a   Cucherat, M ^b   Duhaut, P ^a   Ninet, J ^a   Boissel, J P ^b  

^a EDOUARD HERRIOT HOSPITAL   (France)

^b Centre Cochrane Francais   (France)

Author keywords

Deep vein thrombosis; Duration of anticoagulants; Meta analysis; Oral anticoagulant therapy; Pulmonary embolism; Venous thromboembolism

Indexed keywords

ANTICOAGULANT AGENT;

ANTICOAGULANT THERAPY; BLEEDING; CLINICAL TRIAL; DEEP VEIN THROMBOSIS; HUMAN; LUNG EMBOLISM; META ANALYSIS; PRIORITY JOURNAL; REVIEW; RISK FACTOR; THROMBOEMBOLISM; TOPOGRAPHY; VEIN THROMBOSIS;

ANTICOAGULANTS; HUMANS; VENOUS THROMBOSIS;

EID: 0034538018     PISSN: 09575235     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001721-200012000-00002     Document Type: Review

References (43)

1. A population based perspective of the hospital incidence and case fatality rates of deep vein thrombosis and pulmonary embolism
2. Incidence of venous thromboembolism verified by necropsy over 30 years
3. Antithrombotic therapy for venous thromboembolic disease
4. Management of deep vein thrombosis and pulmonary embolism. A statement for healthcare professionals
5. Management of venous thromboembolism
6. Drug trials that have influenced our practice in the treatment of venous thromboembolism
7. Evolution of therapies in deep vein thrombosis management
8. Traitement anticoagulant pour maladie thromboembolique veineuse: Durée optimale de prescription des Antivitamines-K. Revue de la littérature
9. The optimal duration of anticoagulant therapy for venous thrombosis
10. Oral anticoagulation after a first episode of venous thromboembolism: How long? How strong?
11. Optimal duration of oral anticoagulant therapy following deep vein thrombosis of lower limbs
12. A comparison of six weeks with six months of oral anticoagulant therapy after a first episode of venous thromboembolism
13. The long term clinical course of acute deep venous thrombosis
14. Recurrent venous thromboembolism after deep vein thrombosis
15. Long term outcomes of deep vein thrombosis
16. Length of hospital stay for treatment of deep vein thrombosis and the incidence of recurrent thromboembolism
17. Bleeding complications of oral anticoagulant treatment: An inception cohort prospective collaboration study (ISCOAT)
18. Bleeding complications in oral anticoagulant therapy. An analysis of risk factors
19. Anticoagulant related bleeding: Clinical epidemiology, prediction, and prevention
20. Bleeding and thromboembolism during anticoagulant therapy. A population based study in Rochester Minnesota
21. The risk for and severity of bleeding complications in elderly patients treated with warfarin
22. Prospective evaluation of an index for predicting the risk of major bleeding in outpatients treated with warfarin
23. Hemorrhagic complications of anticoagulant treatment
24. Major bleeding after hospitalization for deep vein thrombosis
25. Optimal duration of oral anticoagulant therapy: A randomized trial comparing four weeks with three months of warfarin in patients with proximal deep vein thrombosis
26. A comparison of three months of anticoagulation with extended anticoagulation for a first episode of idiopathic venous thromboembolism
27. Duration of anticoagulant therapy in venous thromboembolism
28. The duration of oral anticoagulation after deep vein thrombosis: A randomised study
29. One-month versus six months therapy with oral anticoagulants after symptomatic deep vein thrombosis
30. A comparison of 3 and 6 weeks anticoagulation in the treatment of venous thromboembolism
31. Optimum duration of anticoagulation for deep vein thrombosis and pulmonary embolism
32. Three-months compared with one-year of oral anticoagulant treatment after a first idiopathic deep vein thrombosis: The Warfarin Optimal Duration Italian Trial - WODIT study
33. A comparison of three and six months of oral anticoagulant therapy after a first episode of proximal deep vein thrombosis or pulmonary embolism and comparison of six and twelve weeks after isolated calf deep vein thrombosis
34. The duration of oral anticoagulant therapy after a second episode of venous thromboembolism
35. Oral anticoagulation in venous thromboembolism: Decisions based on more than mere feelings
36. Oral anticoagulant therapy: Efficacy, safety and the low-dose controversy
37. Equal effectiveness of very low intensity anticoagulation and standard low intensity anticoagulation: A pilot study
38. The risk of recurrent deep vein thrombosis among heterozygous carriers of both factor V Leiden and the G20210A prothrombin mutation
39. Comparison of long versus short duration of anticoagulant therapy after a first episode of venous thromboembolism. A meta-analysis of randomized controlled trials
40. Practical methodology of meta-analyses (overview) using individual patient data
41. Assessing treatment-time interaction in clinical trials with time to event data: A meta-analysis of hypertension trials
42. Assessing the quality of randomized clinical trials: Is blinding necessary?
43. Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses?